Christmas holiday round-up
As the biotech markets turned bullish the sector’s ups and downs continued.
As the biotech markets turned bullish the sector’s ups and downs continued.
After a rollercoaster existence Cellular Biomedicine Group has a new name, and new deals with AstraZeneca and J&J.
Yet another rich ADC deal is struck as Bristol Myers Squibb ties up with China’s SystImmune.
Yet another ADC deal sees AbbVie buy ImmunoGen, ending a 40-year rollercoaster ride with a 100% overnight premium.
Novartis and Gracell place further bets on shortened production times, with Bristol waiting in the wings.
The new deal comes as Carvykti manufacturing problems continue and 2seventy dials down Abecma expectations.